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[571 ABSTRACT 
The metastatic potential of tumors can be evaluated by the 
quantitative detection of urokinase and DNA. The cell 
sample selected for examination is analyzed for the presence 
of high levels of urokinase and abnormal DNA using ana- 
lytical flow cytometry and digital image analysis. Other 
factors such as membrane associated urokinase, increased 
DNAsynthesis rates and certain receptors can be used in the 
method for detection of potentially invasive tumors. 
21 Claims, 2 Drawing Sheets 
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presence or absence of uPA, since the extractions are from 
tissues containing some normal cells, some cancer cells that 
may have no (or very little) uPA and those that may have 
significant amounts of uPA. (Schmidt, M. et al, “Tumour- 
5 associated fibrinolysis: the prognostic relevance of plasmi- 
nogen activators uPA and tPA in human breast cancer.” 
Blood Coagulation and Fibrinolysis 1: 695-072, 1990). 
Also cells from primary lung and colon tumor produce more 
uPA than cells from metastatic tumors, but different methods 
of extraction and assays give widely variable results 
(Markus, G. et al., “Plasminogen activator secretion of 
human tumors in short-term organ culture, including a 
comparison of primary and metastatic colon tumors.” Can- 
cer Research 43: 55-7-5525, 1983.). 
It recently has been shown in cancer cells that the HMW 
active form of urokinase, bound to the tumor cell membrane, 
is responsible for the local lysis of the extracellular matrix, 
hence the tissue invasion mechanism for metastasis. (Hollas, 
W., Blasi, F., and Boyd, D. “Role of urokinase receptor in 
facilitating extracellular matrix invasion by cultured colon 
20 cancer.” Cancer Research 51: 3690-3695, 1991.). The 
unbound uPA and the LMW form is not responsible for local 
dissolution of extracellular matrix in the immediate vicinity 
of the metastatic tumor cell. (Cubellis, M. V., Wun, T. and 
Blasi, F. “Receptor-mediated internalization and degradation 
25 of urokinase is caused by its specific inhibitor PAI-1.” 
EMBO Journal 9: 1079-1085, 1990.). Thus the direct mea- 
surement of membrane-bound urokinase is more important 
to the prognostic accuracy than is measurement of all 
urokinase (membrane-bound and free uPA) present in cells 
Total urokinase has been measured from tumor tissue and 
secretion by cultured explants. These are difficult to quan- 
titate from biopsy to biopsy, especially if the measurements 
are made on a large group of cells. The data obtained is an 
average value of all normal and cancer cells, rather than a 
35 measurement of each individual cell. However, direct mea- 
surements of intracellular and extracellular urokinase have 
not been made previously. 
A DNA content histogram of normal cells shows a single 
diploid peak (at G, phase) and a tetraploid peak (at G2+M 
40 phase). In most tumors, abnormal DNA content of tumor 
cells is detected as a second G, peak or multiple peaks. 
Abnormal DNA (DNA aneuploidy) is considered as an 
independent indicator of tumor aggressiveness and poor 
prognosis that is used to supplement cytopathology grading. 
45 Flow cytometry can be used to measure total DNA content 
as shown in U.S. Pat. No. 4,780,406, Dolbeare et al. entitled 
Flow Cytometric Measurement of Total DNA and Incorpo- 
rated Halodeoxyuridine issued Oct. 25, 1988, which is 
incorporated herein by reference. Cells disassociated and 
prepared for flow cytometry can be analyzed for cell cycle 
stage as well as DNA content simultaneously. Flow cytom- 
eter measurement of the percentage of proliferating tumor 
synthesizing DNA (S-phase cells) is. an independent indi- 
cator of malignancy. High percentages (15-20%) of S-phase 
55 tumor cells usually indicates an aggressive malignancy and 
usually correlates well with abnormally high DNA content. 
The labeling index (LI) obtained by pulse-labeling cells with 
DNA precursors represents the rate that DNA is being 
synthesized in tumor cells. Usually, a L b 4 %  is associated 
6o with a higher probability of recurrent malignancy. (Merkel, 
D. E. Dressler, L. G. and McGuire, W. L., “Flow cytometry, 
cellular DNA content and prognosis in human malignancy.” 
J. Clin. Oncology 5: 1690-1703, 1987.) 
SUMMARY OF THE INVENTION 
Amethod has been developed for quantitative detection of 
urokinase and correlating the urokinase levels to the DNA 
10 
3o or in the tissue specimen. 
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1 
QUANTITATIVE METHOD OF MEASURING 
METASTATIC ACTIVITY 
This application is a continuation of application Ser. No. 
081097,186, filed Jul. 27, 1993, now abandoned. 
ORIGIN OF THE INVENTION 
The invention described herein was made by an employee 
of the United States Government and may be manufactured 
and used by or for the Government of the United States of 
America for governmental purposes without the payment of 
any royalties thereof or therefor. 
BACKGROUND OF THE INVENTION 
Tumor cells of some cancers secrete enzymes that break 
down the intracellular matrix and invade adjacent tissues. 
The production of serine protease enzymes such as plasmi- 
nogen activator enzymes have been observed in connection 
with the metastasis of tumor cells into healthy tissues. 
Plasminogen activator, enzymes have been linked to cancer 
detection, using assays of enzymes extracted from the tumor 
cells (Camiolo, S. M., Markus, G. and Piver, M. S. “Plas- 
minogen activator content of gynecological tumors and their 
metastases.” Gynecolocical Oncology 26: 364-373, 1987) 
or assays of supernatants from tissue culture of the tumor 
cells. (Hasui, Y. et al., “Comparative study of plasminogen 
activators in cancers and normal mucosa of human urinary 
bladder.” Cancer Research 49: 1067-1070,1989. Harvey, S. 
R., et al., “Secretion of plasminogen activators by human 
colorectal and gastric tumor explants.” Clin. Expl. Metasta- 
sis 6: 431450,  1988.) 
Urokinase-type plasminogen activator (urokinase or 
uPA), a serine protease, is not produced in most normal cells, 
except at low levels in certain types of normal kidney cells, 
colon and gastric mucosa, and endothelial cells lining small 
arteries. Urokinase (uPA) can be present in the tissues in 
several molecular forms,. The inactive proenzyme (scuPA) 
is composed of 411 amino acids. ScuPa is converted to the 
active enzyme by cleavage at Lys.158-Ile.159, loss of the 
Lys.158 and formation of the double chain, high molecular 
weight form (HMW-uPA) that is 54 kDaltons. A low 
molecular weight form (LMW-uPA) can also be formed by 
cleavage of the HMW-uPA at Lys.135-Lys.136 giving a 33 
KDa active enzyme. 
The active urokinase enzymes convert plasminogen into 
plasmin, which in turn, dissolves intravascular fibrin blood 
clots and intracellular fibrin matrix components as well as 
activating collagenases, laminases, and other related 
enzymes which are important to the anchorage and growth 
regulation of cells. Urokinase is produced in a number of 
tumors such as lung, colon, gastric, uterine, breast, brain 
cancer and malignant melanoma. High levels of urokinase 
(>3.5 ugimg of total protein) extracted from breast tumor 
tissues is an indicator for high risk of recurrence and shorter 
patient survival times. Janicke, et al. Fibrinolysis 4:69-78, 
1990. Data from these clinical studies showing that a) 
measurements of uPA in plasma are of no value and that b) 
measurements of uPA in cytosol fractions give some prog- 
nostic value (0.12 benign vs. 1.65 ngiml in metastatic breast 
cancer) and c) measurements of the uPA extracted from all 
of the tumor cells by Triton-X 100 treatment have even more 
significance (0.23 vs. 3.2122.40 ngimg of metastatic breast 
cancer). However, the standard deviation (S.D.) of these 
measurements represents 265% for benign breast cancer and 
275% for metastatic tissues. Clearly, cell extractions cannot 
make the precise distinctions that are necessary as to the 
5,869,238 
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content and additionally to the DNA synthesis rate for 
evaluation of metastatic potential of tumor cells. First, the 
cells to be examined and evaluated are selected. The cells 
can be obtained from known tumor cell lines cultured for 
research purposes, from tumor biopsies or cytological 
samples from patients or any other source of tissue to be 
examined for metastatic activity of tumor cells. The cell 
sample preparations are incubated with antibodies specific to 
urokinase in order to directly measure its presence in the 
isolated cells on a cell by cell basis. The sample of cells may 
be prepared in suspension for analysis by analytical cytom- 
etry techniques such as flow cytometry, digital image analy- 
sis or sectioned and prepared as histology slides for digital 
image analysis. The intranuclear DNA also is labeled or 
stained (using labels or staining including propidium iodide, 
4,6-diamidine-2-phenylindole, Hoechst 33258 and others 
known to those skilled in the art) to allow quantitative 
measurements of DNA content. Viable cells also can be 
pulse-labeled with DNA precursors, BdUr, or IdUr for a 
specific uptake period, then incubated with fluorescent- 
labeled antibodies against the precursor to quantitatively 
measure the DNA synthesis rates in those cells. Measure- 
ments of DNA and urokinase also are made on the same 
cells. DNA and urokinase measurements, may be made 
essentially simultaneously if flow cytometry is used, or 
sequentially from the same source cell population. 
The cells or histology sections are incubated with anti- 
bodies or anti-antibodies specific for urokinase. Antibodies 
or anti-antibodies to specific forms of urokinase may also be 
used. The antibodies can be monoclonal or polyclonal 
antibodies that bind specifically to urokinase. Further, intra- 
cellular urokinase is measured as well as extracellular uroki- 
nase which is outside or associated with the cell membrane 
outer surface. 
The antibodies specific to urokinase may be labeled with 
a fluorescent marker detectable by analytical cytometry 
techniques. Also DNA content and synthesis rate based on 
DNA stains or pulse-labeled uptake of DNA precursors is 
measured by image analysis and flow cytometry. The same 
cell sample can be measured for DNAcontent and urokinase 
by vital staining the DNA and labeling the urokinase with a 
marker so that both the DNA and urokinase can be measured 
simultaneously using two-color image analysis or flow 
cytometry. 
The presence of urokinase, particularly the inactive 
proenzyme scuPA and the high molecular weight form H, is 
correlated to DNA content to determine if the profile of the 
urokinase to DNA ratio is within a range indicating meta- 
static activity. The cells are measured individually on a cell 
by cell basis so that the population examined can be ranked 
to determine whether a high percentage of the cells have 
high urokinase and abnormal DNA levels that indicates 
metastatic activity. Relatively high urokinase and abnormal 
DNA will indicate the need for aggressive oncology, radia- 
tion or immunologic cancer therapy and adjuvant treatment 
following surgical excision of the tumor. 
In addition to urokinase and DNA content, other factors 
for evaluating metastatic potential can be used with the 
method of this invention. DNA synthesis rates indicating 
aggressive tumor growth can be measured as described 
above and correlated with cell surface receptors for tumor 
growth factors such as EGF and hormones such as estrogen 
and progesterone. Also, other antibody specific markers that 
may be helpful in indicating the stage of tumor development 
may be used in conjunction with this method. For instance 
a quantitative measurement for plasminogen activator 
inhibitor, urokinase receptor and other associated hormone 
receptors have been made with the urokinase measurements. 
4 
By establishing a correlation between urokinase and DNA 
content and labeling for DNA synthesis rate a screening 
process can be used to identify metastatic tumor cells. The 
isolated tissue is examined for cells containing urokinase. 
s Initial urokinase measurements may be made directly with 
fluorescent labeled antibodies or indirectly with anti-uPa 
antibodies and fluorescent secondary antibodies or by assays 
for enzyme activity or by other biochemical means. Cells 
without a significant amount of urokinase need not be 
i o  examined further. For samples with cells with higher than 
normal urokinase, then DNA content is measured. If the 
urokinase levels are high in cells with abnormal DNA 
content, the direct measurement of extracellular, especially 
membrane-bound, and intracellular urokinase content can be 
is made. The correlation between abnormal DNA content and 
extracellular urokinase would then be made. Cells or popu- 
lations of cells that do not meet the initial screening criteria 
for metastatic potential do not have to undergo the more 
intensive steps of direct measurement for membrane bound 
20 and intracellular urokinase per cell. The screening process 
can incorporate the other measurements used in the method 
for evaluating the presence of metastatic activity. The pres- 
ence of urokinase receptors, plasminogen activator 
inhibitors, tumor growth factors and membrane associated 
Heretofore, the mean urokinase content of tissue extracts 
or culture supernatants generally measured as compared to 
total protein has been examined to indicate potential for 
metastatic decrease or tumor recurrence. The unique mea- 
30 surement and correlation of urokinase content to DNA 
content of the same cells or same sample can give a 
quantitative indication of metastatic activity of the tumor, 
which indicates immediate concerns about the spread of the 
cancer from the primary tumor and therefore more aggres- 
35 sive post-operative treatments. No previous method has 
been developed to accurately measure the intracellular 
urokinase content, membrane-bound urokinase and cellular 
secretion levels and then correlate those urokinase levels 
with DNA content, DNA synthesis, and other markers of 
40 aggressive tumor growth to determine the metastatic poten- 
tial in an individual patient. 
zs hormone receptors also can be measured. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 A  is a graphic representation of DNA found in CS 
45 glioma cells, measured by fluorescent flow cytometry, which 
shows the DNAcontent relative to the stage of the cell cycle. 
FIG. 1B is a two dimensional plot of the log fluorescence 
from urokinase (ordinate) vs. the log fluorescence from the 
DNAcontained in the CS glioma cells, as measured by flow 
cytometry. 
FIG. 2A is a graphic representation of DNA found in 
HBR09 glioma cells, measured by fluorescent flow 
cytometry, which shows the DNA content relative to the 
FIG. 2B is a two dimensional plot of the log fluorescence 
from urokinase (ordinate) vs. the log fluorescence from the 
DNA contained in the HBR09 glioma cells, as measured by 
flow cytometry. 
55 stage of the cell cycle. 
DETAILED DESCRIPTION OF THE METHOD 
The method for analysis of the metastatic potential of 
cells can be used for diagnostic, research, or any other 
purpose. It is not the intent to limit the type of cell that can 
65 be isolated and evaluated nor to limit the type of histological 
tissue that can be labeled with the fluorescent anti-urokinase 
antibodies for measuring the urokinase in situ in the tissue 
60 
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biopsy. The following is a general description of the method 
including the preferred method. It is not intended to disclose 
every mode to practice the invention, and substitutions and 
modifications to the steps described herein may be made 
without departing from the scope of the invention. 
Antibodies can be formed against the two major molecu- 
lar forms of uPA using established methods of isolating the 
HMW-uPA or LMW-uPA urokinase protein then immuniz- 
ing animals to produce the antibodies. Typically, the uPA 
antigen is isolated from human urine or cell culture medium 
by absorption chromatography. Most commercial anti-uPA 
antibodies are murine antibodies made against human uroki- 
nase. The commercial antibodies (such as AD#394 and 
AD#3689 American Diagnostics, Inc.1 can detect the 54 
kDA HMW-uPA Or the 33 
but they cannot distinguish between the 54 kDAHMW-uPA 
active and Proenzyme SCUpA molecular forms (also 54 
kDA). The HMW-uPA is used by the tumor cells to rapidly 
invade adjacent tissue. Therefore, it is important to distin- 
guish between HMW-uPA with its proenzyme scupA and An alternate preferred method involves the parallel mea- LMW-uPA, The commercial anti-uPA antibodies can inhibit 2o surement of membrane bound urokinase, intracellular 
Another alternative method for analysis of cellular uroki- 
nase is by flow cytometry. The membrane-bound urokinase 
can be measured directly by incubating the cells with the 
fluorescent labeled antibodies against the different molecu- 
5 lar forms of urokinase. Whereas, the intracellular urokinase 
can only be measured after the cell wall has been partially 
permeated by chemical or electrochemical poration tech- 
niques. Then the anti-uPA antibodies can penetrate the cell 
and attach to the urokinase in the cytoplasm. Laser activated 
flow cytometry can be used to determine uPA content per 
cell. The cells containing uPA can be sorted as they pass 
through the flow cytometer and selected for uPA content. 
The selected cells are further examined by digital image 
analysis for cytoplasmic or intracellular uPA and 
extracellular, membrane bound uPA. A large population of 
cells can be examined using flow cytometry and fluorescent 
antibodies as a screening method prior to digital image 
analysis, 
LMW-uPA forms of 
the normal enzymatic activation of plasminogen to plasmin, 
Presently, none of the commercial anti-uPA antibodies are 
(cytoplasmic) urokinase levels 
Of the fluorescent micrographs and 
digita1 image 
with DNA 
specific for detection of the actual cleavage sites where 
verts scuPA to HMW-uPA. Measurements of scuPA may be 2s 
performed by preincubation of duplicate samples with and If the cells are not actively metastasizing they have no 
without plasmin and measuring the presence of HMW-uPA urokinase or very low levels of urokinase including low 
in both samples and quantifying the difference attributable to amounts of membrane-bound urokinase and high levels of 
scuPA. Plasminogen Activator Inhibitor (PAI-1 and/or PAI-2). 
Anti-uPA antibodies can be used as the primary anti-body 30 These are characteristic of non-invading, non-metastasizing 
in sandwich assays or in permeabilized cytology primary tumors or metastatic tumor cells that already are 
preparations, wherein either the anti-uPA antibodies can be well established at the metastatic site. The tumor cells that 
fluorescently labeled or a secondary, fluorescent labeled, are actively invading adjacent tissues and metastasizing are 
antibody can be attached to the anti-uPA primary antibody; characterized by high levels of membrane-bound HMW-uPA 
thus permitting fluorescence image analysis or laser acti- 35 or S C ~ P A  type urokinase, abnormal levels of DNA and low 
vated flow cytometry analysis to determine the amount of levels of PAI-1. The quantitative measurements of DNA, 
‘Ontent and DNA synthesis rates as measured by flow 
activation of the proenzyme (scuPA) occurs. Plasmin con- cytometry Or image DNA levels are 
to the aggressive growth Of the tumor 
the intracellular and membrane bound urokinase in each cell. urokinase and PAI-1 enable precise comparisons to establish 
Also the anti-uPA antibodies themselves can be conjugated the unique metabolic state of the tumor cells that are 
with markers having detectable physical or chemical prop- preparing for or actively metastasizing. 
erties. The markers are well known in the field of immu- 40 The method of this invention also includes the step of 
noassays. The preferred method utilizes markers with measuring the DNAcontent in the cells isolated from patient 
detectable light emissions by fluorescence, phosphorescence biopsies. The nuclear DNA content can be determined by 
or luminescence, however, markers that absorb light, such as labelling with vital stains such as propidium iodide (PI), 
peroxidase, and radioactive labels can also be used. Primary Hoeschst stain, DAPI or by antibodies reactive to DNA or a 
and secondary detection of the antibodies may be useful in 45 DNA precursor as described in U.S. Pat. No. 4,780,406, 
the invention with different types of cell or tissue samples issued Oct. 25, 1988, to Dolbeare and Gray which has been 
The cells to be examined are first isolated. The cells may incorporated by reference herein. Urokinase expression and 
be from a tumor, fine-needle biopsy or cytological sample. secretion is regulated by certain cytokines and hormones. It 
The anti-uPA antibodies are incubated with the cells. In a has been shown that the recurrence of breast and other 
preferred method for examination of intracellular and so cancers is related to the number of estrogen (ER) and 
membrane-bound extracellular urokinase, the cells are progesterone receptors (PgR) found on the surface of the 
labeled with fluorescent markers for digital image analysis. tumor cells. The use of fluorescent antibodies against ER 
Using digital image analysis the anti-uPA antibodies can be and PgR enables the simultaneous measurement of receptor 
located and quantitatively measured in both the cytoplasm density on the cell surface to be compared with the DNAand 
and where the urokinase is bound to the cell membrane. 5s the urokinase levels in normal and tumor cells. The hormone 
These measurements are used statistically to give the rela- receptor levels can be measured either by flow cytometry or 
tive distribution and absolute concentrations of membrane- digital image analysis and then directly compared with the 
bound and cytoplasmic urokinase in biopsy cells. This data 
can then be used to statistically compare the urokinase levels using flow cytometry, but also can be measured by image 
and distribution in those cells with tumor cells from other 60 cytometry. 
patients, thus giving a quantitative benchmark as to the By using different fluorescent labels or markers that can 
metastatic state of those tumors in each individual patient. be measured at essentially the same time at two or more 
This data also can be used in retrospective studies where the different wavelengths the same cell population that is exam- 
time to reoccurrence, degree of metastasis and morbidity are ined for urokinase can be simultaneously assayed for PAI, 
known. Cumulative data on patients can then be used to 65 DNAcontent, DNAsynthesis rate or hormone receptors. For 
provide a prognostic indicator of the degree of active example, fluorescent antibodies to both the DNA or DNA 
metastasis in primary tumors. precursors and urokinase forms can be used with different 
urokinase levels. The DNA content is preferably measured 
5,869,238 
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emission characteristics, thus the flow cytometer can simul- 
or more antibodies. Digital image capture also can be 
performed at multiple wavelengths thus enabling measure- 
ments of more than one intracellular protein or membrane 5 
receptor and DNA in the same tissue specimens. 
Digital analysis measurement of the amount of urokinase, 
in the cytop~asm or membrane-bound, also can be used with 
the measurement of DNA content by flow cytometry, The 
identical cell population is not necessarily used for each 
same cells that were isolated from the surgical biopsy. 
Another alternative method also measures the synthesis 
rate of DNA in the cells by pulse labeling with DNA 
precursor amino acids (BdUR or IdUR) and then labeling 
with fluorescent antibodies against the DNA precursor to 
content for each cell type in various stages of the cell cycle. 
HMW-UPA (with commercial anti-uPA antibodies HMW- 
uPA that cannot distinguish between scuPA and active 
HMW-UPA). FIG. 1B illustrates the correlation of the uPA 
content vs. the DNA content in the CS cells, while FIG. 2B 
illustrates a different pattern of uPA content vs. the DNA 
content in the more invasive HBR09 cells. Table 1 summa- 
rizes the Presence of DNA and UpA in the cs and HBR09 
content between the CS and HBR09 cell types is more 
Pronounced when the cells are in the resting cells (G1IGO) 
compared to the those cells that are active synthesizing DNA 
and dividing (S & G2+M). In other tumor cells the difference 
may be greater in S and G, phases. 
taneously measure two or more color fluorescence Of the two The Same cells were measured by flow cytometry for 
analysis, however, since aliquot samples are used from the tumor cell lines. It should be noted that the difference in uPA 
TABLE 1 
SIMULTANEOUS FLOW CYTOMETRY MEASUREMENT OF DNA AND uPA 
IN HUMAN BRAIN TUMOR CELLS 
Mean Fluorescence Levels - (DNA) PI and uPA (FITC-anti-uPA MAb) 
PHASE 
(CELL CYCLE) GlIGo S + G2M 
CELL I.D. % Cells DNA S.D. uPA S.D. % Cells DNA S.D. uPA S.D. 
IgG (Control) 78.8 16.7 2.00 0.74 0.15 0.6 29 3.60 2.18 0.11 
cs 77.3 17.2 1.50 1.90 0.21 7 29.1 0.41 4.74 0.24 
HBR09 82.6 9.9 1.00 12.22 0.17 15 17.4 2.20 15.48 0.18 
RATIO OF uPA HBR09ICS = 3.27 RATIO of uPA HBR09ICS = 6.43 
determine the amount of incorporation per unit time. 
(Gratzner, H. G. and Leif, R. C. “An immunofluorescence 
method for monitoring DNA synthesis by flow cytometry.” 
Cytornetvy 6: 385-389, 1983.). The DNA synthesis rate can 
either be measured by flow cytometry or fluorescence image 
analysis and thus compared directly to the levels of uroki- 
nase in the tumor cells. 
Another alternative method is measurement of urokinase 
using fluorescence image analysis of de-parafhized or 
frozen histology sections from biopsy tissues. DNA can be 
measured simultaneously using a vital fluorescent stain (PI 
or DAPI) or fluorescent labeled antibodies against BdUR or 
IdUR that emits fluorescence at a different wavelength than 
does the labeled anti-uPA antibodies. Supporting flow 
cytometry data can be obtained from thick sections from the 
tumor specimens, whereupon the cells are dissociated, 
treated with RNAse, the nuclei freed from the cytoplasm and 
flow cytometry performed on the nuclei. This data is then 
compared to the urokinase levels or image analysis data on 
cells taken from the same biopsy tissue. 
To illustrate the method of this invention the correlation 
of urokinase on a cell by cell basis and DNA content have 
been examined in two glioma cell lines obtained from 
surgical biopsies removed from two different patients (CS 
and HBR09) with brain tumors. Comparisons were made 
among: 1) autofluorescence measured in cells treated with a 
non-specific immunoglobin (IgG) as controls, 2) green fluo- 
rescence measured from cells treated with FITC-labeled 
antibodies against urokinase, and 3) red fluorescence mea- 
sured from the DNA in the same cells stained with pro- 
pidium iodide, using cell samples that were disassociated for 
flow cytometry. The CS cells are less invasive and metastatic 
brain tumor cells than HBR09 cells. 
The DNA was measured by flow cytometry for the CS 
cells and HBR09 cells and FIGS. 1 A  and 2A show the DNA 
Table 1 is a summary of simultaneous flow cytometry 
measurements using fluorescent markers for DNA and uPA 
35 in IgG-treated control cells; CS cells (illustrative of a less 
invasive glioma tumor); and HBR09 cells from a more 
invasive tumor. DNA values are based on the mean fluo- 
rescence from propidium iodide (PI) stain while uPA values 
are based on FITC-labeled, anti-uPA antibodies that bind to 
40 HMW-UPA and scuPA. The DNA and uPA values for the 
IgG controls are mean measurements of the non-specific 
autofluorescence measured from the cells in the PI and FITC 
bandpass regions, respectively. The control cells had very 
little uPA, especially in the resting phase (GlIGO). The CS 
45 cells in G,/G, contain 1.7 times more DNA than the HBR09 
cells, but the HBR09 cells contain 6.4 times more UPA. The 
same relationship is present in the S+G,, phases, however, 
the HBR09 cells contain only 3.3 times more uPA than do 
the CS cells. 
FIGS. 1 A  and 2A are graphic representations of the cell 
distribution data for DNA content, obtained from the flow 
cytometer printouts and summarized in Table 1. The legends 
show the relative distribution of the cells in the GJG,, S, 
and G,,phases of the cell cycle. FIG. 1Ais  a semilog plot 
5s of the CS cell number vs. the DNAcontent, where the DNA 
is represented by the log fluorescence from PI staining 
(abscissa). FIG. 2A is a semi-log plot of the cell number vs. 
the DNA content for the HBR09 cells. 
FIGS. 1B and 2B are graphic representations of the uPA 
60 and DNA content for the CS cells and HBR09 cells, 
respectively, measured by two-color flow cytometry as sum- 
marized in Table 1. DNAwas measured by the DNAspecific 
fluorescent dye propidium iodide and uPA was measured by 
FITC-labeled anti-urokinase antibodies. In FIGS. 1A and 2A 
65 zone 1 is the fluorescence measurement for the DNAcontent 
in the cells at GJG,, zone 2 is for the cells in S+G,+,, and 
zones 3 and 4 represent low-level  background 
50 
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/autofluorescence levels below the gating value selected 
from identical runs with negative controls. In general, the 
DNA fluorescence for the HBR09 cells in the S and G, 
phase (FIG. 2B, zone 2) is higher than the CS cells (FIG. l B ,  
zone 2). Furthermore, the distribution of HBR09 cells con- 
taining high levels of uPA in the resting phase (FIG. l B ,  
zone 1) is more focused than the CS cells (FIG. 2B, zone 1.) 
Eighty-eight percent of the HBR09 cells in the resting phase 
and 96% of the cells in S and G,,(zone 2) have high levels 
urokinase in contrast to the CS cells where 42% in the 
resting phase and only 54% of the cells in S and G, have 
significant levels of urokinase. Also the mean content of uPA 
per HBR09 cell is greater than the CS cells in all phases of 
the cell cycle. 
Flow cytometry can be used for disassociated cell samples 
to initially screen for the abnormal DNA content and uPA 
profile indicating aggressive tumors. Cells with abnormal 
DNAand high levels of uPAparticularly in the S phase merit 
attention for potentially aggressive tumor tissue and further 
examination by digital image analysis. However, the analy- 
sis by flow cytometry using this method may be sufficient 
with existing pathological procedures and tests to make a 
determination on treatment of a dangerously malignant 
tumor. 
Image analysis was performed on fluorescent uPA anti- 
bodies in CS and HBR09 cells. Image analysis can quantify 
the presence of uPA by measuring the fluorescence emitted 
by labeled antibodies that are bound directly to uPA. Table 
2 illustrates the comparison of flow cytometry analysis and 
digital image analysis of fluorescent-labeled uPA antibodies, 
wherein each sample of glioma cells were split into two 
groups for parallel assays of uPA. Table 2 shows the high 
levels of uPA in CS and HBR09. However, in-comparison 
HBR09 has much higher levels of uPA than CS as confirmed 
by both flow cytometry and image analysis. Note that the 
image analysis method show a greater ratio of UPA in the 
HBR09 cells as compared to the CS cells and that the 
standard deviation of the mean fluorescence is smaller 
(8-9%) compared to the flow cytometry data (10-35%) on 
the same cells. 
TABLE 2 
COMPARISON OF UROKINASE IN CONTROL 
AND BRAIN CANCER CELLS USING 
FLUORESCENT-LABELED uPA ANTIBODIES 
MEAN 
CELL FLUORES- MEMBRANE- 
LINE CENCE S.D. BOUNDuPA S.D. 
FLOW IgG (Control) 2.0s 
CYTO- cs 6.13 
METRY HBR09 32.25 
IMAGE IgG (Control) 1.86 
ANAL- CS 11.3 
YSIS 
HBR09 74.1 
RATIO HBR09ICS = 7.5611 
RATIO HBR09ICS = 5.2611* 
- 0.3 
0.1 
11.3 
0.1 
0.76 78.3 3.41 
6.34 821.9 47.8 
- 
- 
(8%) (4%) 
(9%) (6%) 
HBR09ICS = 10.511 
*RATIO HBR09ICS = 7.4 after autofluorescence is subtracted 
Image analysis has the further benefit of measuring the 
membrane bound uPA. Using the method of this invention, 
a determination of the presence of membrane bound uPA is 
made when indicated. The fluorescent microscope can be 
focused on different levels within each cell before the 
images are digitized, thus it can be distinguished if the uPA 
is on the cell surface or within the cell cytoplasm. Digital 
10 
levels can also be selected so that areas of the cell surface or 
cytoplasm emitting a given fluorescence intensity can be 
measured and labeled, thus providing quantitative data and 
a visual reference for use with other cytopathological evalu- 
s ations. The presence of uPA at the membrane indicates a 
tumor cell that is actively invading adjacent tissues or 
migrating to a remote site to establish a new metastatic 
tumor. In Table 2 the membrane bound uPA is significantly 
higher in the more invasive HBR09 than in the CS cells. The 
i o  use of image analysis is precise and can be used on tissue 
such as biopsies on slides in which the cells have not been 
disassociated. Image analysis can also be used to quantify 
they different forms of urokinase in the same cells by using 
different fluorescent antibodies for different forms of uroki- 
The method also includes screening for the presence of 
plasminogen activation inhibitors (PAI) PAI-1 and PAI-2. 
Antibodies specific to PAI-1 and PAI-2 with a fluorescent 
label may be used. An aggressive tumor will have higher 
20 levels of abnormal DNA (tetraploid or greater) while meta- 
static cells will have low levels of PAI-1 or PAI-2 and high 
levels of uPA. 
Membrane bound PAI-1 and PAI-2 measurements can 
also be very important since the PAI can compete with the 
25 uPA for binding to the uPA receptor on the tumor cell 
surface. The method can also incorporate fluorescent anti- 
bodies specific for the uPA receptors on the cell surface. 
Comparison of the DNA content, DNA synthesis rate, uPA 
content, membrane-bound uPA, PAI and uPA receptor den- 
30 sity in tumor cells can give the clinician much clearer insight 
into the metastatic potential of each tumor that is biopsied. 
The combined method of cytology testing described herein 
is required to provide a systematic way of acquiring the 
required data and accuracy needed for determining the true 
35 metastatic potential of a particular tumor. This information 
can provide the basis for custom therapeutic regimens that 
are designed for each cancer patient’s circumstance at the 
time of the biopsy. 
The examples and methods described herein exemplify 
the invention and are not intended to limit the scope of the 
invention in any way. Other methods of practicing the 
invention will be apparent to those skilled in the art. 
IS nase. 
4o 
I claim: 
1 .  A method of measuring metastatic activity by direct 
quantitative detection of urokinase and DNA for use in the 
evaluation of the presence of tumor cells with invasive 
characteristics comprising the steps of 
45 
(a) selecting the cells to be examined; 
(b) incubating a sample of the cells with antibodies 
specific to urokinase and a label specific to DNA, 
(c) measuring directly the antibodies specific for the 
amounts of urokinase present in the sample on a cell by 
cell basis; 
(d) measuring the DNAcontent simultaneously as step (c) 
in the same sample of the cells isolated in step (a) on 
a cell by cell basis; and 
(e) identifying the cell populations in the sample on a cell 
by cell basis for DNA aneuploidy and high urokinase 
amounts; and 
( f )  further evaluating the cell populations identified in step 
(e) for DNA content for resting cells (GlIGO) and 
synthesizing and dividing cells (S and G2+M); and 
(g) correlating DNAcontent for resting cells (GlIGO) and 
synthesizing and dividing cells (S and G2+J with high 
urokinase levels to identify tumor cells with more 
SO 
55 
6o 
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invasive characteristics which have lower DNAcontent 
and higher urokinase content as compared to the high 
DNA content and low urokinase content of tumor cells 
with less invasive characteristics in the restinn ahase 
12. A method of measuring metastatic activity by direct 
quantitative detection of urokinase and DNA for use in the 
evaluation of the presence of metastatic activity in tumor 
cells comprising the steps of 
V I  
(GlIGO). 5 
2. A method of measuring metastatic activity by direct 
quantitative detection of urokinase and DNA of claim 1 
wherein the urokinase antibodies are specific to the group 
selected from scuPA and HMW-uPA or mixtures thereof. 
quantitative detection of urokinase and DNA of claim 1 
wherein steps (c) and (d) the simultaneous measurements are 
performed by analytical cytometry and the antibodies spe- 
cific to urokinase and the label specific to DNA have a 
marker detectable by analytical cytometry techniques. 
4. A method of measuring metastatic activity by direct 
quantitative detection of urokinase and DNA of claim 1 
wherein the antibodies specific to urokinase are monoclonal 
antibodies. 
quantitative detection of urokinase and DNA of claim 1 
wherein the antibodies specific to urokinase are polyclonal 
antibodies. 
6. A method of measuring metastatic activity by direct 
quantitative detection of urokinase and DNA of claim 1 zs 
wherein the antibodies specific to urokinase have a fluores- 
cent marker. 
7. A method of measuring metastatic activity by direct 
quantitative detection of urokinase and DNA of claim 1 
comprising the additional step of measuring DNA synthesis 30 
by analytical flow cytometry performed on the same cell 
sample simultaneously with the DNA content measured in 
step (d). 
8. A method of measuring metastatic activity by direct 
auantitative detection of urokinase and DNA of claim 1 35 
3. A method of measuring metastatic activity by direct i o  
is 
5. A method of measuring metastatic activity by direct 20 
(a) selecting the cells to be examined; 
(b) incubating a sample of the cells with antibodies 
specific to urokinase and a label specific to DNA, 
(c) measuring directly the antibodies specific for the 
amounts of urokinase present in the sample on a cell by 
cell basis using flow cytometry; 
(d) simultaneously as step (c) measuring directly the DNA 
content of the cells isolated in step (a) on a cell by cell 
basis; 
(e) identifying and isolating the cell populations in the 
sample on a cell by cell basis with DNA aneuploidy and 
high urokinase levels; and 
( f )  measuring the intracellular and membrane bound 
urokinase using digital image analysis of individual 
cells in the cell population identified and isolated in 
(g) simultaneously with step ( f ) ,  using digital image 
analysis of individual cells for the cell populations 
identified and isolated in step (e), measuring DNA 
content for resting cells (GlIGO) and synthesizing and 
dividing cells (S and G2+J; and 
(h) correlating DNAcontent for resting cells (GlIGO) and 
synthesizing and dividing cells (S and G2+J which 
have lower DNAcontent as compared to the high DNA 
content of tumor cells with less invasive characteristics 
at the resting phase (GlIGO) with high intracellular and 
high membrane bound urokinase to identify tumor cells 
with more invasive characteristics which have high 
membrane bound urokinase as compared to tumor cells 
with less invasive characteristics. 
13. A method of measuring metastatic activity by quan- 
step (e); 
comprising the additional steps of incubating a sample of the titative detection of urokinase and DNA of claim 12 com- 
cells with plasminogen activator inhibitor antibodies and prising the additional measurement DNA synthesis rate in a 
measuring quantitatively the presence of bound plasmino- sample of the cells identified and isolated in step (e) and 
gen activator inhibitor antibodies by digital image analysis further correlating the DNA synthesis rate of cells with 
and correlating the plasminogen activator inhibitor content 40 higher urokinase content whereby metastatic cells have a 
to the urokinase content identifying the more metastatic cells lower DNA synthesis rate than non-metastatic cells. 
that have comparably low levels of plasminogen activator 14. A method of measuring metastatic activity by direct 
inhibitor content and high levels of urokinase content. quantitative detection of urokinase and DNA of claim 12 
9. A method of measuring metastatic activity by direct wherein the antibodies specific to urokinase are monoclonal 
quantitative detection of urokinase and DNA of claim 1 45 antibodies. 
comprising the additional steps of incubating a sample of the 15. A method of measuring metastatic activity by direct 
cells with antibodies against plasminogen activator inhibi- quantitative detection of urokinase and DNA of claim 12 
tors and measuring quantitatively the presence of plasmi- wherein the antibodies specific to urokinase are polyclonal 
nogen activator inhibitor bound antibodies by flow cytom- antibodies. 
etry and correlating the plasminogen activator inhibitor SO 16. A method of measuring metastatic activity by direct 
content to the urokinase content identifying the more meta- quantitative detection of urokinase and DNA of claim 12 
static cells that have comparably low levels of plasminogen wherein the antibodies specific to urokinase have a detect- 
activator inhibitor content and high levels of urokinase able light emitting marker. 
content. 17. A method of measuring metastatic activity by direct 
10. A method of measuring potential metastatic activity ss quantitative detection of urokinase and DNA of claim 12 
by direct quantitative detection of urokinase and DNA of wherein the label specific to DNA has a detectable light 
claim 1 comprising the additional steps of selecting cells emitting marker. 
with membrane-bound urokinase, incubating a sample of the 18. A method of measuring metastatic activity by direct 
cells with urokinase receptor markers and measuring quan- quantitative detection of urokinase and DNA of claim 12 
titatively the urokinase receptor density and further corre- 60 comprising the additional steps of incubating a sample of the 
lating these cells with high urokinase receptor density for cells with plasminogen activator inhibitor antibodies and 
those cells with high urokinase content and low plasminogen measuring quantitatively the presence of bound plasmino- 
activator inhibitor content which are characteristic of high gen activator inhibitor antibodies by digital image analysis 
invasiveness. and correlating the plasminogen activator inhibitor content 
11. A method of measuring metastatic activity by direct 65 to the urokinase content identifying the more metastatic cells 
quantitative detection of urokinase and DNA of claim 1 that have comparably low levels of plasminogen activator 
wherein the label specific to DNA is a measurable marker. inhibitor content and high levels of urokinase content. 
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19. A method of measuring metastatic activity by direct 
quantitative detection of urokinase and DNA of claim 12 
comprising the additional steps of incubating a sample of the 
cells with antibodies against plasminogen activator inhibi- 
nogen activator inhibitor bound antibodies by flow cytom- 
etry and correlating the plasminogen activator inhibitor 
cells with urokinase receptor markers and measuring quan- 
titatively the urokinase receptor density and further corre- 
lating those cells with high urokinase receptor density with 
those cells with high urokinase content and low plasminogen 
invasiveness. 
tors and measuring quantitatively the presence Of plasmi- activator inhibitor content which are characteristic of high 
content to the urokinase content identifying the meta- 
static cells that have comparably low levels of plasminogen 
21. The method Of measuring metastatic activity by direct 
quantitative detection of urokinase and DNA of claim 12 
activator inhibitor content and high levels of urokinase 
content. 
20. A method of measuring metastatic activity by direct 
quantitative detection of urokinase and DNA of claim 12 
wherein the urokinase antibodies are specific to the group 
consisting of scuPA, LMW-UPA and HMW-UPA or mix- 
tures thereof. 
comprising the additional steps of incubating a sample of the * * * * *  
